Detailed answers about PENCHARZ PET-CT AND NUC MED REPORTING LIMITED, including incorporation, status, business activity, and accounts information.
When was PENCHARZ PET-CT AND NUC MED REPORTING LIMITED founded?
PENCHARZ PET-CT AND NUC MED REPORTING LIMITED was officially incorporated on 27 February 2025 and is registered under company number 16280670. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is PENCHARZ PET-CT AND NUC MED REPORTING LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of PENCHARZ PET-CT AND NUC MED REPORTING LIMITED?
PENCHARZ PET-CT AND NUC MED REPORTING LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does PENCHARZ PET-CT AND NUC MED REPORTING LIMITED do?
PENCHARZ PET-CT AND NUC MED REPORTING LIMITED operates in the following sector: 86210 - General medical practice activities. This provides insight into the company's primary business activity and industry focus.
What is PENCHARZ PET-CT AND NUC MED REPORTING LIMITED's registered address?
The registered office address of PENCHARZ PET-CT AND NUC MED REPORTING LIMITED is 134 BUCKINGHAM PALACE ROAD, LONDON, ENGLAND, SW1W 9SA. This is the official address filed with Companies House for legal and statutory correspondence.
Is PENCHARZ PET-CT AND NUC MED REPORTING LIMITED financially stable?
Financial accounts for PENCHARZ PET-CT AND NUC MED REPORTING LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.